Europe Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market
No. of Pages: 76 | Report Code: TIPRE00025059 | Category: Life Sciences
No. of Pages: 76 | Report Code: TIPRE00025059 | Category: Life Sciences
The Europe small intestinal bacterial overgrowth (SIBO) diagnostics market includes the consolidated markets for Germany, France, the United Kingdom, and rest of Europe. Germany dominated the market in 2020. Germany is among the leading country in Europe that have well-developed healthcare industry and offers world-class facilities. The growth of Germany small intestine bacterial overgrowth market is majorly attributed to the considerable prevalence of abdominal conditions such as irritable bowel syndrome and others. For instance, according to a recent data by the United European Gastroenterology Journal, an estimated 15.0% of the German population were suffering from constipation. Moreover, around 15.0%-25.0% of the German population suffers from irritable bowel syndrome. Such conditions are estimated to raise the prevalence of SIBO, which will eventually drive the adoption of SIBO diagnostics in the country. Substantial number of abdominal surgical procedures are also projected to accelerate the prevalence of SIBO. For instance, around 100,000 laparotomies are performed each year in the country. Such surgeries are likely to generate favorable environment for growth of SIBO, which will ultimately accelerate adoption of SIBO diagnostics in Germany. These factors will have constructive impact of market growth. Advantages of breath test and increasing prevalence of IBS and SIBO are the major factor driving the growth of the Europe small intestinal bacterial overgrowth (SIBO) diagnostics market.
In case of COVID-19, Europe is highly affected specially France followed by Italy and Spain. These countries also registered maximum deaths in the past few months. Several countries in the Europe imposed social distancing and lockdown policies to prevent the spread of virus. Moreover, disturbances in production as well as transportation had negative impact on the growth of Europe small intestinal bacterial overgrowth diagnostics market. Due to the lockdown and medical emergency various trades were put on hold. Therefore, the receiving the product on time have delayed various laboratory workflow and have resulted in a long process of deliveries of laboratory equipment, medical devices, and consumables. In addition, rapid and sudden emergence of coronavirus disease in Europe postponed all elective diagnostic and surgical procedures. For instance, according to a recent study published by the American Journal of Managed Care in 2021, the healthcare facilities in UK witnessed around 80.0% reduction in number of diagnostic procedures due to lockdown and social distancing policies. This factor is significantly responsible for negative impact on the growth of Europe SIBO diagnostics market. Thus, the delayed processes in the healthcare sector is expected to show slow growth for Europe's small intestinal bacterial overgrowth (SIBO) diagnostics market in the coming few years.
Strategic insights for the Europe Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 46,628.70 thousand |
| Market Size by 2028 | US$ 62,001.00 thousand |
| Global CAGR (2021 - 2028) | 4.2% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Diagnosis
|
| Regions and Countries Covered | Europe
|
| Market leaders and key company profiles |
The geographic scope of the Europe Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The Europe small intestinal bacterial overgrowth (SIBO) diagnostics market is expected to grow from US$ 46,628.70 thousand in 2021 to US$ 62,001.00 thousand by 2028; it is estimated to grow at a CAGR of 4.2% from 2021 to 2028. Advent of NGS technologies to diagnose SIBO is expected to fuel the market growth. Growing microbiome research and rising technological developments have increasingly helped in the accurate diagnosis of SIBO. In recent years, gut microbiome research has become a hot topic for researchers that have enabled to understand the heterogeneity of the SIBO. Researchers have been using technologies such as next-generation sequencing (NGS) methods, Human Microbiome Project (HMP), and the Metagenomics of the Human Intestinal Tract (MetaHIT) projects as essential references concerning the microbiota structure in human bodies. These technologies have helped understand the biomarkers of guts, which are associated with a wide variety of metabolic disorders such as inflammatory bowel diseases (IBD). In addition, the IBS related symptoms of SIBO such as excessive gas, bloating, abdominal pain, constipation, and diarrhea have helped in gaining SIBO much attention for its diagnosis. The traditional methods such as hydrogen breath tests performed using substrates such as lactulose or glucose are not efficient enough to identify SIBO. However, due to their reproducibility, simplicity, and safety of the procedure, they are now being substituted for more uncomfortable and expensive techniques that were conventionally used in gastroenterology. Therefore, there is an active debate going on for the diagnosis and management of SIBO. Various research studies conclude that high-throughput sequencing analysis such as 16S rRNA gene sequencing for the small intestinal microbiome is a better interpreter of gastrointestinal symptoms than the conventional methods. The accuracy and efficiency of the NGS methods are much helpful to diagnose the gut microbiome or SIBO and offer treatment through antibiotics, pre, and probiotics supplementation. Thus, the growing research for NGS technologies to diagnose SIBO is expected to set the trend for the Europe market’s growth during the forecast period.
In terms of diagnosis, the breath testing segment accounted for the largest share of the Europe small intestinal bacterial overgrowth (SIBO) diagnostics market in 2020. In terms of type, the hydrogen-predominant SIBO segment held a larger market share of the Europe small intestinal bacterial overgrowth (SIBO) diagnostics market in 2020.
A few major primary and secondary sources referred to for preparing this report on the Europe small intestinal bacterial overgrowth (SIBO) diagnostics market are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Aerodiagnostics, LLC.; Commonwealth Diagnostics International; Genova Diagnostics; SIBOTest; and The Functional Gut Group.
Some of the leading companies are:
The Europe Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market is valued at US$ 46,628.70 thousand in 2021, it is projected to reach US$ 62,001.00 thousand by 2028.
As per our report Europe Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market, the market size is valued at US$ 46,628.70 thousand in 2021, projecting it to reach US$ 62,001.00 thousand by 2028. This translates to a CAGR of approximately 4.2% during the forecast period.
The Europe Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market report:
The Europe Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market
